Anti-Osteoclastic Effect of Zinc Studied in MCF-7 Induced Osteoclastogenesis by Nagalakshmi, K et al.
Nagalakshmi et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):94-97  
ISSN: 2250-1177                                                                                  [94]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.08.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Anti-Osteoclastic Effect of Zinc Studied in MCF-7 Induced Osteoclastogenesis 
Nagalakshmi K, Shila S, Rasappan P* 
VRR Institute of Biomedical Science, (Affiliated to University of Madras) Kattupakkam, Chennai, India 
 
ABSTRACT 
Bone which a key structural support of the body, undergoes dynamic micro structural remodelling all over life to control automatic stress and 
calcium requirement in the body. A number of risk factors including oxidative stress, apoptosis and abnormal intracellular Ca2+ metabolism 
have been postulated to play a function in the inception and progress of bone osteolysis. Cancer cells establish a tight relationship with the host 
tissue, secreting factors that stimulate or inhibit bone cells, receiving signals generated from the bone remodelling activity, and displaying some 
features of bone cells. This interplay between tumour and bone cells alters the physiological bone remodelling, leading to the generation of a 
vicious cycle that promotes bone metastasis growth. Zinc is one of the most relevant minerals to human health, because of its antioxidant 
properties. The present study was aimed to investigate protective role of zinc against bone metastasis. In the present study, TRAP positive 
multinucleated cell count was low compared to CM treated cells. Zinc treatment suppressed MCF-7 induced mRNA levels of cytoplasmic 1 
(Nfatc1), TRAP and Cathepsin-K. Hence, it can be concluded that zinc decreases osteoclastogenesis induced by MCF-7 cells. 
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INTRODUCTION 
Zinc is one of the essential minerals for human health 
because it serves as a co-factor for over 300 enzymes and 
2000 transcription factors. Zinc is an important mediator of 
cellular signalling [1,2]. As an anti-inflammatory agent, zinc 
provides structural stability to cell membranes and it is also 
an important regulator of gene expression [3, 4, 5]. Zinc 
is a structural component of the enzyme superoxide 
dismutase present in the cytoplasm of cells [6]. Therefore, 
maintaining adequate concentrations of zinc in the cell 
compartments is essential for the proper functioning of the 
antioxidant defense system [7]. Zinc is bound to 
metallothionein under normal physiological conditions. In 
oxidative stress conditions, the micronutrient is released 
from its complex with metallothionein and is redistributed 
in the cells to exert antioxidant actions [8,9].  
Oxidative stress is characterized by an imbalance between 
oxidants and antioxidants, due to the excessive production 
of reactive oxygen species (ROS) and the reduction in the 
rate of its removal by the antioxidant defence system. This 
metabolic disturbance favours the oxidation of biomolecules, 
contributing to the oxidative damage in the cells and tissues 
and consequently to the development of several chronic 
diseases such as obesity, diabetes and cancer [10,11,12]. 
Moreover, antioxidants and anti-carcinogenic mechanisms 
associated with zinc homeostasis appear to play an 
inhibitory role in the growth of neoplastic cells. Zinc acts in 
the protection against genomic instability and genetic 
mutations. In this sense, the superoxide dismutase is an 
anticarcinogenic enzyme. It inhibits the initiation, 
promotion, and progression phases in mammary 
carcinogenesis [13].  
Bone is the third most frequent site of metastasis after lung 
and liver and typically indicates a short-term prognosis in 
cancer patients [14, 15]. Bone metastasis causes morbidity 
with severe pain, impaired mobility, fractures, spinal cord 
compression, bone marrow aplasia, and hypercalcemia [16]. 
Bone is a fertile soil for metastasis. Indeed, it supplies a 
unique environment for metastasis represented by the 
hematopoietic marrow in long bones and axial skeleton for 
which breast cancer cells have a preference [17,18]. 
Osteolysis is the most common manifestation of bone 
metastasis [19].  Once established in bone, the tumor cells 
secrete soluble factors promoting osteoclast differentiation 
and resorption. Growth factors are mobilized from the 
resorbed bone matrix, supporting tumor cells’ survival and 
proliferation. In turn, the growing tumor releases pro-
osteolytic factors, fostering further osteolysis [20]. The 
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mechanism of bone metastases and bone destruction found 
in cancer is also related to the direct activation of osteoclasts 
by RANKL, which is secreted by cancer cells [21,22].In the 
present study an attempt has been made to evaluate the 
anti-osteoclastogenic effect of Zinc in MCF-7 induced 
osteoclastogenesis.  
MATERIALS AND METHODS  
Culture media: (DMEM) dulbecco's modified eagle's 
medium with fetal bovine serum to a final concentration of 
10%. 
Conditioned media (CM): MCF-7 cell lines secrete the 
components necessary for osteoclatogenesis that is the 
components necessary for cell differentiation form 
precursor monocytes to osteoclasts. 
Cell lines : The monocyte /macrophage-like cell line RAW 
264.7 has been one of the most commonly used myeloid cell 
line for more than 40 years. RAW 264.7 cell line remains 
stable through passages: from passage no. 10 up to passage 
no. 30.  MCF-7 is a breast cancer cell line isolated in 1970 
from a 69-year old Caucasian woman[28].MCF-7 is the 
acronym of  Michigan Cancer Foundation-7, referring to the 
institute in Detroit where the cell line was established in 
1973 by Herbert Soule and co-workers[29]. 
MTT assay: RAW264.7 cells were maintained in growth 
media with or without Zinc (10, 30, 60, 80,100, 200 Micro 
Molar) for 24 hours. Cell viability assays were performed 
using an EZcytox cell viability assay kit (Daeillab Service, 
South Korea) according to the manufacturer’s instructions. 
Briefly, the cells were plated in 96-well plates at 1 × 104 cells 
per well and cultured in growth media. At the indicated time 
points, cells were incubated for 4 h at 37°C . The number of 
viable cells in triplicate wells was measured at an 
absorbance wavelength of 450 nm. 
TRAP staining kit to detect osteoclasts  
Measurement of TRAP activity and TRAP staining TRAP 
activity was measured from osteoclast culture supernatants 
using a TRAP Staining kit (Kamiya Biomedical Company). 
Supernatants (30 μl) were incubated for 3 hours at 37°C 
with 170 μl of the chromogenic substrates in a tartrate-
containing buffer. TRAP activities were measured in terms of 
the absorbance at a wavelength of 540 nm. TRAP was 
stained using a similar method as described above. Cultured 
cells were incubated with a fixative for 5 minutes at room 
temperature, washed with distilled water, and treated for 20 
minutes at 37°C with the chromogenic substrate in tartrate-
containing buffer. After staining, TRAP-positive 
multinucleated (nuclei ≥ 3) cells were counted using manual 
counting or a nuclei counter plug-in in the Image J program. 
Cell fractionation 
RAW264.7 cells at 70–80% confluence were incubated in α-
MEM containing RANKL (35 ng/ml), with or without ZnSO4, 
for the indicated times, washed, and scraped in cold PBS. Cell 
pellets were fractionated into cytoplasmic and nuclear 
fractions using a NE-PER Nuclear and Cytoplasmic 
Extraction Reagents kit (Pierce, Rockford, IL). 
Real-time reverse transcription-PCR 
RNA was extracted from control and osteoclasts on the 
indicated days using TRIZOL reagent (Invitrogen, Carlsbad, 
CA).cDNA was reverse transcribed using random hexamers 
and SuperScript-III reverse transcriptase (Invitrogen).The 
cDNA was used in real-time PCR with a KAPA SYBR FAST 
ABI Prism qPCR kit (Kapa Biosystems). The specific primer 
pairs are shown in Table 1. Nfatc1 and other mRNAs were 
measured using a StepOne (Applied Biosystems) Real-Time 
PCR System. The PCR program was initiated for 20 seconds 
at 95°C, followed by 40 thermal cycles of 3 seconds at 95°C 
and 30 seconds at 60°C, and terminated for 15 seconds at 
95°C, 1 minute at 60°C, and 15 seconds at 95°C. Data were 
analyzed according to the comparative cycle threshold (Ct) 
method [30] and were normalized to GAPDH in each sample. 
We examined individual gene expression in triplicate and 
repeated each experiment more than three times.RT-PCR 
was performed using total RNA and gene specific primers. 
Elevated levels of transcript were analyzed using RNA gel 
stained with ethidium bromide.  
Statistical analysis: 
The results are shown as the mean ± standard deviation 
(S.D.) from at least three independent experiments. The 
differences between groups were analysed using Student’s t-
tests and p < 0.05 was considered statistically significant. 
RESULTS AND DISCUSSION: 
The results of MTT assay (Fig 1) revealed the inhibitory 
concentration at 80µ M Zinc Sulphate 
                   
 
Figure 1: MTT assay for cytotoxicity of Zinc 
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Plate 1 depicts the TRAP staining for for Raw 264.7 (Group I ) Osteoclasts (Group-II) and Osteoclasts +Zinc (Group-III) cells 
 
Group I:  Raw 264.7                Group-II: Osteoclasts              Group-III: Osteoclasts +Zinc 
 
 
Figure 2  TRAP STAINING  
Figure 2 depicts the TRAP staining for Raw 264.7 (Group I ) Osteoclasts (Group-II) and Osteoclasts +Zinc (Group-III). From 
figure 2, it is observed that osteoclast production was comparatively decreased in zinc treated cells. 
Plate 2:  mRNA expression patterns of osteoclastogenic gene by PCR analysis 
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Zinc treatment inhibited breast cancer-induced 
osteoclastogenic genes expressions. RAW264.7cells were 
cultured in the presence or absence of CM along with or 
without Zinc for 48 h, and subsequently RT-PCR was 
performed using total RNA and gene specific primers. 
Elevated levels of transcript TRAP and Cathepsin K (Cath K) 
were found in the cases of CM-treated cells as compared with 
control and CM-induced transcript levels were diminished 
with Zinc treatment.CM-induced NFATc1 levels were 
diminished by Zinc treatment. 
According to Denis RC and et al.,  in vitro analysis of the 
influence of breast cancer tumor cells on osteoclast 
formation or survival, or both, demonstrated that breast 
cancer cells induced a dramatic increase in the number of 
osteoclasts detected in culture [23]. In the present study, 
Zinc treatment inhibited MCF-7 induced osteoclastogenic 
genes expressions. RAW264.7cells was cultured in the 
presence or absence of CM along with or without Zinc for 48 
h, and subsequently RT-PCR was performed using total RNA 
and gene specific primers. Elevated levels of transcript TRAP 
and Cathepsin K were found in the cases of CM-treated cells 
as compared with control and CM-induced transcript levels 
were diminished with Zinc treatment. CM-induced NFATc1 
levels were diminished by Zinc treatment.This ultimately 
inhibits osteoclast differentiation. In earlier studies Hie et al. 
demonstrated that Zn treatment could inhibit RANK 
expression during osteoclast differentiation [24]. Park et al 
have indicated that impairment of Nfatc1 activation is the 
cause of suppression during osteoclastogenesis. Zinc inhibits 
osteoclast differentiation by suppression of Ca2+-
Calcineurin-NFATc1 signaling pathway [25]. Our results are 
in par with previous findings. Our studies reveal for the first 
time that MCF-7 induced metastatic osteoclastogenesis was 
suppressed in the presence of Zinc. It is noteworthy that the 
expression of NFATc1 the master regulator and the 
osteoclastogenic genes TRAP and Cathepsin-K is down 
regulated by Zinc.   
CONCLUSION 
Bone metastases are serious complications which affects the 
quality of life, and performance state of cancer individuals. 
To overcome these complications the agents inhibiting 
osteolytic activity, and activity of RANK are in use. However, 
identification of the major molecules involved in this process 
could allow the discovery of new therapeutic targets for bone 
lesions. From the present study, it is observed that Zinc 
down regulates the osteoclastic genes of TRAP, Cathepsin –K 
AND NFATc1. Novel Zinc based agents can be developed to 
prevent, and treat bone metastasis, and further studies 
should be conducted investigating other molecules which 
play a role in the pathogenesis of bone metastasis. 
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